Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    New Vaccine Development Platform Could Fight Deadly, Multi-Drug Resistant Bacteria

    By Global Biodefense StaffJanuary 30, 2021
    Interaction of resistant bacteria with human white cell. Credit: NIAID
    Share
    Facebook LinkedIn Reddit Email

    A new vaccine development platform has proven effective in protecting against deadly, hard-to-treat infections caused by multi-drug resistant bacteria, thanks to a collaborative endeavor led by the Uniformed Services University (USU). This could ultimately help prevent battlefield infections, as well as common hospital-acquired infections in patients undergoing routine surgeries.

    This research, “Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates” was published this week in the journal Vaccines, as part of a special issue ‘Vaccines for Infectious and Chronic Diseases.’ The effort was led by Dr. Michael J. Daly, a professor in USU’s Department of Pathology, Dr. Gregory J. Tobin, president of Biological Mimetics, Inc., and Dr. Daniel Zurawski at the Walter Reed Army Institute of Research (WRAIR).

    The rapid vaccine development platform, now shown to be highly effective against multi-drug resistant bacteria, has recently also been used to develop protective vaccines against RNA viruses: Venezuelan Equine Encephalitis Virus, Chikunguyna Virus, and Sabin polioviruses. Importantly, the USU platform developed by Daly’s team could be quickly adapted to generate inactivated whole-virus SARS-CoV-2 vaccines.

    The multi-drug resistant A. baumannii bacteria first became a major threat to U.S. troops during the Gulf War. The bacteria cause a range of life-threatening illnesses including pneumonia, septicemia, and wound infections, but there are few treatment options when it comes to multi-drug resistant-bacteria. Since then, the World Health Organization (WHO) has listed A. baumannii in their highest category of pathogens posing an imminent threat to human health. Today in the U.S., there are about 45,000 hospital-acquired A. baumannii infections each year, and around one million globally.

    “This will be a great benefit not only for our service members, as it could prevent trauma-related infections after battlefield injuries, but also to the general public, who are often exposed to this MDR pathogen in civilian hospital settings,” Daly said.

    Funding for this study was provided through an STTR Phase II contract HDTRA 1-17-C-0030 from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense to BMI, Inc. with USU as the US Government partner, managed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF).

    Radiation-Inactivated Acinetobacter baumannii Vaccine Candidates. Vaccines, 27 January 2021.

    Article adapted from original story by Sarah Marshall, Uniformed Services University.

    A. baumannii Antimicrobials Chikungunya Drug Development Editor Pick HAIs Polio Venezuelan Equine Encephalitis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleShould People Who Have Recently Had COVID-19 Be Vaccinated?
    Next Article Self-Swabs vs. Caregiver Swabs for COVID Tests: New Study Shows Similar Accuracy

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.